

# Sonoma Pharmaceuticals, Inc.

Investor Presentation

October 2024



# Legal Disclaimers

## **INVESTOR PRESENTATION**

This communication is for informational purposes only. The information contained herein does not purport to be all-inclusive. The data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness of the assumptions made within or the accuracy or completeness of any information contained herein. Any data on past performance is no indication as to future performance. Sonoma Pharmaceuticals, Inc. and its subsidiaries ("Sonoma" or, the "Company") assumes no obligation to update the information in this communication. This presentation is not an offer to buy or the solicitation of an offer to sell Sonoma securities.

## **FORWARD-LOOKING STATEMENTS**

Except for historical information herein, matters set forth in this presentation are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries.

These forward-looking statements are identified by the use of words such as "believe," "achieve," and "expect," among others. Forward-looking statements in this presentation are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, the Company will not have sufficient capital to implement its business plan, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking statements, except as required by law.

## **TRADEMARKS AND INTELLECTUAL PROPERTY**

All trademarks, service marks, and trade names of the Company and its subsidiaries or affiliates used herein are trademarks, service marks, or registered trademarks of the Company as noted herein. Any other product, company names, or logos mentioned herein are the trademarks and/or intellectual property of their respective owners.



# About Sonoma

Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Sonoma's products are clinically proven to reduce itch, pain, scarring, and irritation safely and without damaging healthy tissue. In-vitro and clinical studies of HOCl show it to safely manage skin abrasions, lacerations, minor irritations, cuts, and intact skin.



Sonoma's products are sold either directly or via partners in 55 countries worldwide. Sonoma actively seeks new distribution partners.



# Investment Highlights

## Hypochlorous Acid Industry Leader

Over 20 years of experience developing and manufacturing products containing HOCl, over 100 research articles, papers and clinical and case studies, over 50 active U.S. and international patents, and continual product innovation

21 U.S. FDA clearances as 510(k) medical devices, CE marks for over 39 products, and extensive worldwide regulatory clearances

Utilized on millions of patients worldwide without a single report of serious adverse effect

## Diverse Global Healthcare Business

Focused on billion-dollar markets in Rx and OTC dermatology, wound care, eye, oral and nasal care, podiatry, animal health and non-toxic disinfectants, treating common injuries and managing irritations

Robust and diverse international partner network selling into over 55 countries and extensive worldwide regulatory clearances means products can be commercialized faster

FDA registered medical device manufacturing capabilities in Mexico lowers COGS and creates opportunities for volume plays

# Sonoma's Microcyn® Technology



## Patented, Stabilized Triple-Action Topical Technology

- HOCl kills microbes including bacteria, fungi and viruses while assisting healing
- Relieves pain and itch
- Improves wound care by cleaning and moistening the wound and peri-wound area
- Safely manage skin abrasions, lacerations, minor irritations, cuts, burns, and intact skin
- Applications in dermatology include atopic dermatitis, scar treatment and daily care

## May replace other treatments with side effects or health concerns

- Overused antibiotics may cause deadly epidemics such as MRSA
- May replace steroids for some patients
- Avoids harmful ingredients such as benzoyl peroxide

## Cost Effective

- Reduces hospital/physician visits
- Medicare/hospital savings from reduced hospital stays



# Sonoma's Microcyn<sup>®</sup> Technology



## Unparalleled Safety

- No drug-to-drug interaction or contraindications
- Millions of patients treated worldwide without a single report of serious adverse effect
- 30+ human clinical trials with over 1,500 patients
- Products contain all-natural hypochlorous acid

## Industry Leader

- Strong U.S. and international regulatory portfolio
- Longer shelf life than most competitors while retaining efficacy
- Available in solution, hydrogels and in combination with silicone for scar treatment
- White label available with custom packaging and design
- Established Microcyn<sup>®</sup> brand
- State of the art manufacturing





# Over 100 research articles and case and clinical studies showcasing both the efficacy and safety of our Microcyn® technology

Received: 20 June 2019 | Revised: 23 November 2019 | Accepted: 10 December 2019  
DOI: 10.1111/jocd.12286

REVIEW ARTICLE

WILEY

## Topical stabilized hypochlorous acid: The future gold standard for wound care and scar management in dermatologic and plastic surgery procedures

Michael H. Gold MD, FAAD<sup>1,2,3,4</sup> | Annelie Andriessen PhD<sup>5</sup> |  
Ashish C. Shrivastava MD, FAAD<sup>6,7</sup> | Patrick Bitter Jr MD, FAAD<sup>8</sup> |  
Sameel Chikheif MD, FAAD, FACMS<sup>9,10</sup> | Joel L. Cohen MD, FAAD, FACMS<sup>11,12</sup> |  
Chris W. Rabb MD, PhD<sup>13</sup>

<sup>1</sup>Yale Skin Care Center, Nashville, TN, USA  
<sup>2</sup>Yale University School of Medicine, Nashville, TN, USA  
<sup>3</sup>Nashville University School of Nursing, Nashville, TN, USA  
<sup>4</sup>Yale University School of Medicine, Nashville, TN, USA  
<sup>5</sup>Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA  
<sup>6</sup>Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA  
<sup>7</sup>Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA  
<sup>8</sup>Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA  
<sup>9</sup>Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA  
<sup>10</sup>Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA  
<sup>11</sup>Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA  
<sup>12</sup>Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA  
<sup>13</sup>Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA

### Abstract

**Background:** Hypochlorous acid (HOCl), a naturally occurring molecule produced by the immune system, is highly active against bacterial, viral, and fungal microorganisms. Moreover, HOCl is active against biofilms and increases oxygenation of the wound site to improve healing. Natural HOCl is unstable through technology; it can be stabilized into an effective topical antiseptic agent.

**Aim:** This paper focuses on the use of topical stabilized HOCl in wound and scar management for pre-, peri-, and postprocedural use—including its ability to reduce the occurrence of hypertrophic scars and keloids. The role of this product in other skin conditions is beyond the scope of this article.


**Methods:** A panel comprising clinicians with experience in reconstructive surgical procedures met with Zila to discuss literature search results and their own clinical experience regarding topical stabilized HOCl. The panel of key opinion leaders in dermatology and plastic surgery defined key insights and consensus statements on the direction of use for the product.

**Results:** Topical stabilized HOCl provides an optimal wound healing environment and, when combined with silicone, may be ideal for reducing scarring. Additionally, in contrast to chlorhexidine, HOCl used as an antiseptic skin preparation causes no concerns of toxicity or resistance.

**Conclusions:** For wound care and scar management, topical stabilized HOCl offers a powerful microbicidal and antiseptic properties, in addition to potency as a topical wound healing agent; it may offer physicians an alternative to other less desirable wound care measures.

### KEYWORDS

hypochlorous acid technology, postprocedural scar management, stabilized hypochlorous acid, wound care



**Figure 1.** Stability of severe acute respiratory syndrome SARS-CoV-2. (a) Stability of SARS-CoV-2 in dried form. (b) Stability of SARS-CoV-2 in dried form. (c) Stability of SARS-CoV-2 in dried form. (d) Stability of SARS-CoV-2 in dried form. Blue line, 4°C; orange line, 20–25°C; grey line, 30°C

### COVER FOCUS

## Optimizing Wound Healing for Cosmetic and Medical Dermatologic Procedures

Among the options for wound management is hypochlorous acid, a broad-action antimicrobial and inflammatory agent.

BY ASHISH BHATIA, MD, | JEFFREY HSU, MD | TODD SCHLESINGER, MD | AND ROBERT W.

Multiple factors influence wound healing. However, three primary conditions are essential for optimal wound healing with minimal risk of scarring. First, optimal wound healing requires the eradication of pathogenic bacteria and biofilms. Second, optimal wound healing requires an excellent blood supply and proper oxygenation. Finally, the proper immunological healing factors must be present in order for the wound to heal. With these optimal healing “ingredients” in place, the outcome is minimal scarring, rapid healing, and good structure and function of the healed wound site.

Physicians who perform aesthetic procedures, especially energy-based treatments or injections, are particularly focused on rapid healing, minimum pain, minimum downtime, and optimal appearance. A controlled wound is created with these tools and technologies, is associated with improved healing compared to uncontrolled or traumatic wounds. Nevertheless, proper wound care serves to further support healing for optimal outcomes. Consider that, in some cases, aesthetic physicians are creating controlled wounds with the intention to remove existing scars and the need to support wound healing becomes evident.

For dermatologists, wound care generally is focused on post-surgical management for lacerations and excision sites or post-procedural skin care in lowering energy-based procedures or peels. At-home skin prep for excisions or Mohs micrographic surgery is not common. However, many patients interested in aesthetic procedures are advised to implement a skincare routine in advance of the procedure. In the aesthetic patient, retinoids and related compounds, botanical ingredients, growth factors, and antioxidants may be recommended individually or in combination, depending on the patient, the procedure, and the physician preference.

Increasingly, evidence suggests that the care of a wound immediately before a surgery or procedure and the healing phase can have important effects on the outcome. For years, dermatologists have relied on a “sensational” option for pre-procedural skin care: a topical antiseptic to cleanse the skin immediately before a procedure. Commonly used antiseptics include chlorhexidine and povidone-iodine. However, chlorhexidine can be toxic to tissues, especially in the presence of iodine. Povidone-iodine has been associated with allergic reactions and is not recommended for use on the face. Topical antiseptics can also be irritating to the skin, and as has been an important option, chlorhexidine preparations can be used for up to 72 hours of treatment. Use of topical antiseptics for wound care is increasingly common, due to concerns about the use of bacterial resistance. Furthermore, topical care can actively improve scars that reside on it may infect wounds. Additionally, some topical formulations are associated with risks for allergic dermatitis. The associated inflammation in the dermis is detrimental to wound healing and may contribute to scar formation, hyperpigmentation, or hypopigmentation.

Alternative approaches to wound management and scar prevention have been emerging. The use of rich plasma (RP), which is increasingly being used

Accepted: 10 February 2020  
DOI: 10.1111/jocd.12286

REVIEW ARTICLE

WILEY

## Hypochlorous acid gel technology—Its impact on postprocedural treatment and scar prevention

Michael H. Gold MD, FAAD<sup>1,2,3,4</sup> | Annelie Andriessen PhD<sup>5</sup> | Steven H. Dayan MD<sup>6</sup> |  
Sabrina G. Fabi MD<sup>7</sup> | Z. Paul Lorenz MD, FACS<sup>8,9</sup> | Megan-Helen Henderson Berg MD<sup>10</sup>

<sup>1</sup>Yale Skin Care Center, Nashville, TN, USA  
<sup>2</sup>Yale University School of Medicine, Nashville, TN, USA  
<sup>3</sup>Nashville University School of Nursing, Nashville, TN, USA  
<sup>4</sup>Yale University School of Medicine, Nashville, TN, USA  
<sup>5</sup>Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA  
<sup>6</sup>Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA  
<sup>7</sup>Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA  
<sup>8</sup>Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA  
<sup>9</sup>Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA  
<sup>10</sup>Department of Dermatology, University of Illinois at Chicago, Chicago, IL, USA

### Summary

**Background:** A pre- and postprocedural regime aimed at prevention of infection, reduction of inflammation and risk of scarring, is to optimize optimal outcomes.

**Objectives:** The role of a hypochlorous acid containing spray and translucent scar gel formulation that contains modified silicon oil with hypochlorous acid, used alongside pre- and postprocedural treatment and scar management.

**Methods:** For this purpose a literature review was conducted to explore the value of the technology used in pre- and postprocedural regimes. A panel of dermatologists and plastic surgeons who practice in the United States discussed the current search results, taking into account their current clinical practice. A central group period for consensus was used, followed by online reviews of the manuscript.

**Results:** Based on panel discussion, consensus was reached regarding clinical recommendations given for postprocedural treatment and scar management. The hypochlorous acid products are produced with electronics and are classified among medical substances. The technology has demonstrated efficacy and safety for pre- and postprocedural use. The safety of hypochlorous solution use demonstrated to be comparable to that of standard local anesthetics. Small studies demonstrated better results with the scar gel compared to silicone gel regarding the appearance of hypertrophic and keloid scars, relief of associated pruritus and pain.

**Conclusions:** A postprocedural regimen using this technology aimed at preventing infection, reducing inflammation, and promoting healing is proposed to have lower the overall current regimen as it appears to be effective, safe, and well tolerated.

### KEYWORDS

hypochlorous acid technology, postprocedural scar management

### 1 | INTRODUCTION

Optimal outcomes over pre- and postprocedural care and scar management are at the forefront. They are holistic, aesthetic, sensitive and consistency with quality of outcomes to assure a proper healing environment and reduce inflammation. Our consensus system

# Wide Range of Applications



Wound Care



Dermatology



Eye Care



Oral and Dental Care



Animal Health Care



Surface Disinfectants



Podiatry



Nasal Care





## Our Wound Care Business is Growing in the U.S. and Internationally

- Celebrating **20 years** of selling wound care
- In August 2024, we added **Medline Industries, LP** as a U.S. distributor for our wound care products – Medline is one of the largest medical supply distributors in the United States
  - In October 2024, we expanded our partnership with Medline to include distribution in Canada, and OTC wound care sales to retailers in both countries
- We sell wound care across Europe and added a new distributor for wound care in Ukraine in 2024
- Expanding Product Lines: including new options for our **Microcyn® Negative Pressure Wound Therapy Solution** product line.
- Product innovation: In June 2023, we announced a new application of our Microcyn® technology for intraoperative pulse lavage irrigation treatment.



## Industry-Leading Safe and Effective Dermatology Products

- Products to relieve symptoms of atopic dermatitis, reduce scarring, and for daily skin care
- Line of office dispense products targeting growing med spa market
- Eczema seal of approval 
- All natural ingredients 
- No harmful chemicals
- OTC, office dispense, and Rx products available
- Innovating packaging available including high end and cost competitive options
- Continual Product Innovation: Introduced Lumacyn™ Clarifying Mist in 2024, a daily toner formulated to reduce redness and manage blemishes by reducing infections.



## Expanded Eye Care Product Line

- Sonoma has the strongest FDA indications for eye care in the HOCl industry
- OTC and prescription eye care sold into multiples channels
- Strong CE Mark for eye care sales in the EU
- Animal health eye care sold in major chains including PetSmart and Tractor Supply





# Safety in Dermatology Products

Recently, there has been concern by dermatologists that popular **dermatology products** can form **benzene**, a known carcinogen.

- *Citizen petition by Valisure, LLC, an independent testing laboratory for pharmaceuticals, requested an FDA recall of certain over-the-counter and prescription dermatology products containing benzoyl peroxide.*
- *Testing by Valisure showed that benzoyl peroxide in dermatology products from major brands including **Proactiv**, **Clearasil**, and **CeraVe**, can form benzene, a known human carcinogen, at unacceptably high levels.*
- *Previous testing by Valisure has found unacceptably high levels of benzene in common hand sanitizers, as well as in **after-sun products** by brands such as **Hawaiian Tropic** and **Banana Boat**.*

Sonoma's products offer a safe yet highly effective alternative for consumers concerned with harmful ingredients in skin care products.



# Safety in Eye Care

The FDA has issued safety warnings for certain eye products after finding unsanitary conditions in the manufacturing facilities and positive bacterial test results from environmental sampling.

- *The warnings in October 2023 applied to eye drops by brands such as **CVS**, **Rite Aid**, **Target** and **Walmart**, which were then voluntarily recalled by the manufacturer.*<sup>1</sup>
- *Sonoma owns its own state-of-the-art manufacturing facility, used to manufacture all of its products subject to strict FDA guidelines.*
- *Sonoma's eye care products, like all of its products, are extremely safe, and contain all-natural ingredients with no cytotoxins.*

1. <https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-consumers-not-purchase-or-use-certain-eye-drops-several-major-brands-due-risk-eye>

# Robust U.S. and International Distribution Network

## OVER 40 GLOBAL PARTNERS AND GROWING

We continue to:

- Expand our presence in new markets by replicating what works in existing markets
- Add new distribution partners and grow existing relationships
- Co-develop innovative new products with partners
- Work with partners to seek new approvals and certifications





## CUTTING EDGE MANUFACTURING



Currently operating at 30% capacity  
with margin of approximately 35%

- 57,153 square foot state-of-the-art facility
- ISO 9001, ISO 13485 and cGMP certified
- MOH, KFDA, SFDA, KSA, TGA, EN, Biocide and numerous other national listings and approvals
- Shipping to over 55 countries, with multiple methods for shipments
- Highly trained staff of 162 employees
- Additional 11,840 square feet of overflow capacity



Flexible operations capable of CUSTOM LABELING, SIZING, PACKAGING & DISPENSE MODES

High or small volume, large or small batch, delivered in 12 weeks



# Manufacturing Facility



Located in Guadalajara, Mexico



Laboratory



Materials Testing Laboratory



Water Treatment System



Product hoppers



Air System



Packaging Area



Labeling



Boxing



Ready for shipment



Warehouse

# Growth Strategy

## Continue to introduce new high margin products

- Launch new applications of Sonoma's Microcyn® technology for consumer-focused products, including in the dermatology and aesthetic space

## Manufacturing capabilities can support significant future growth, leading to improved margins overall

- Efficient, flexible and FDA-regulated manufacturing facility currently operating at only 30% capacity
- Seek new manufacturing customers to utilize overflow space

## Expand Rx and OTC reach in U.S.

- Increase sales of dermatology products through the direct dispense model that generates Sonoma's highest margins
- Increase direct-to-consumer marketing in niche markets
- Seek retail partners for OTC products
- Expand eye care marketing for Rx and OTC

## Invest in R&D to expand commercialization opportunities

- Seek additional regulatory clearances for expanded indications
- Introduce new technology to new markets
- Fully commercialize robust pipeline of new products via direct-to-consumer sales or distribution partnerships





# New Market Opportunities

Sonoma is expanding its partnerships and product offerings in the eye care, all-natural skin care, medical spa and animal health care industries.

- The global **eye care** market size was estimated at USD \$70.78 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 6.72% from 2024 to 2030.<sup>1</sup>
- The global **natural skin care** products market size was valued at \$6.7 billion in 2021 and is expected to expand at a CAGR of 6.6% from 2022 to 2030.<sup>2</sup>
- The global **medical spa** market size was estimated at USD 18.6 billion in 2023 and is expected to grow at a CAGR of 15.13% from 2024 to 2030.<sup>3</sup>
  - North America dominated the medical spa market with a share of 41.1% in 2023, due to higher expenditure on wellness tourism than other regions.<sup>4</sup>
- The global **animal health** market size was valued at USD 62.40 billion in 2023 and is projected to grow at a CAGR of 9.0% from 2024 to 2030.<sup>5</sup>

1. Grand View Research, *Eye Care Market Report, 2024-2030*, available at <https://www.grandviewresearch.com/industry-analysis/eye-care-market-report>

2. Grand View Research, *Natural Skin Care Products Market Report, 2022-2030*, available at <https://www.grandviewresearch.com/industry-analysis/natural-skin-care-products-market>

3. Grand View Research, *Medical Spa Market Size, Share & Growth Analysis Report 2024-2030*, available at <https://www.grandviewresearch.com/industry-analysis/medical-spa-market>

4. *Ibid.*

5. Grand View Research, *Animal Health Market Size & Share Report, 2024-2030*, available at <https://www.grandviewresearch.com/industry-analysis/animal-health-market>

# Recent Business Developments

## Introduction of new products using our Microcyn® technology


- In September 2024, we announced the consumer-friendly redesign of **Ocucyn® Eyelid & Eyelash Cleanser**.
- In April 2024, we announced expansion of our **Microcyn® Negative Pressure Wound Therapy Solution** product line, now available in 250mL, 450mL and 990mL sizes to meet the diverse needs of healthcare professionals and patients.
- In January 2024, we launched **Lumacyn™ Clarifying Mist**, a new direct-to-consumer skincare product in the United States. Lumacyn is an all-natural daily toner formulated with Microcyn® technology to soothe the skin and relieve irritation.
- In June 2023, we announced a new application of our Microcyn® technology for **intraoperative pulse lavage irrigation treatment**, which can replace commonly used IV bags in a variety of surgical procedures. It is in trial use by hospitals in Europe and launched in the U.S. in November 2023.
- Our **MicrocynAH®** products are now available through **Pets at Home**, with over 450 stores across the UK, through our partner **Compana Pet Brands**
  - In May 2024, we announced expansion of our MicrocynAH® animal health care products in the **Menards®** chain of home improvement stores in the United States, through **Compana Pet Brands**.
- In April 2023, we launched **Podiacyn™ Advanced Everyday Foot Care** direct to consumers for over-the-counter use in the United States.





# Recent Business Developments

## Expanding commercialization opportunities by investing in R&D

- In September 2024, we received a **new 510(k) clearance** from the FDA, including specific over-the-counter indications for the face, eyelid and eyelashes and a smaller product size.
- In March 2023, we announced new EPA claims for **Nanocyn® Hospital-Grade Disinfectant** for effective use against **MRSA, Salmonella, Norovirus, Poliovirus**, and as a **fungicide**. Nanocyn was previously approved for use against **COVID-19** as well as emerging pathogens including **Ebola virus, Mpox, and SARS-CoV-2**. Nanocyn also received the esteemed **Green Seal® Certification** after surpassing a series of rigorous standards that measure environmental health, sustainability and product performance.
  - In August 2024, the Australian TGA approved new claims for use against **C. auris** and **C. diff**.
- **Reliefacyn® Advanced Itch-Burn-Rash-Pain Relief Hydrogel** was awarded the **NATIONAL ECZEMA ASSOCIATION SEAL OF ACCEPTANCE™** 
- A recent publication in the journal *Neurourology and Urodynamics* highlighted the potential for **Microdox®** in the management of urinary tract infections, or UTIs, in children with neurogenic or non-neurogenic bladder dysfunction, concluding that multi-center trials are needed.<sup>1</sup>

1. Singh G-K, Deshpande A, Schlegel G, Starkey M, Taghavi K. The rationale for bladder washouts in children with neurogenic bladder. *Neurourol Urodyn.* 2024;1-6. doi:10.1002/nau.25450



# Recent Business Developments

## Continuously expanding our distributor network

- In August 2024, we announced a new distribution agreement with **Medline Industries, LP** for the marketing and distribution of our wound care products in the **United States**.
  - In October 2024, we expanded our agreement with Medline for marketing and distribution of our wound care products in **Canada**, and the sale of OTC wound care products to retailers in both countries.
- In July 2024, we announced a new distribution agreement with **Smart Healthcare Company** for wound care in **Ukraine**.
- In April 2023, our partner **Te Arai BioFarma Limited** launched **BabySoothe** for diaper rash applications in **Taiwan**.
  - In April 2024, Te Arai launched **Microdacyn** for wound care in **Taiwan**.
- Our partner **Microderm Technologies** recently launched **Dermodacyn** for wound care applications in **Thailand**.
- Our partner **Brill Pharma SL** is now selling Sonoma's eye care products in **Italy**, **Spain**, **Portugal** and **Germany**.
- In January 2023, we entered into a distribution agreement with **Daewoong Pharmaceutical Co., Ltd.**, one of the largest pharmaceutical companies in **South Korea**, for marketing and distribution of **Primocyn™ Skin Solution** products



# Management

**Amy Trombly**  
**CEO**

Amy Trombly is our Chief Executive Officer and also serves on our Board of Directors. She counseled public companies for over two decades in corporate and securities law and mergers and acquisitions, including as the owner and manager of Trombly Business Law, PC. In her earlier career, Ms. Trombly was a Vice President at State Street Bank and Special Counsel at the U.S. Securities and Exchange Commission. Ms. Trombly is a member of the bar in Massachusetts and Colorado.

**Bruce Thornton**  
**COO**

Bruce Thornton has served as our Chief Operating Officer, Vice President of Global Operations, and US General Manager since 2004, and currently as Executive Vice President and Chief Operating Officer. He served as Vice President of Operations for Jomed (formerly EndoSonic Corp.) from January 1999 to September 2003, and as Vice President of Manufacturing for Volcano Therapeutics, an international medical device company, following its acquisition of Jomed, until March 2004. Mr. Thornton received a B.S. in Aeronautical Science from Embry-Riddle Aeronautical University and an M.B.A. from National University. He also has served in the US Army.

**Jerry Dvonch**  
**CFO**

Mr. Dvonch serves as our Chief Financial Officer. He joined us from the SpineCenter Atlanta where he was the controller and Senior Vice President of Finance and Accounting since March 2017. From March 2016 to April 2016 he was a consultant controller for DS Healthcare Group, Inc. Prior to that he was the director for external reporting and director of finance of NeoGenomics Laboratories from July 2005 to July 2015. He has over 10 years of experience with SEC reporting. Mr. Dvonch is a licensed Certified Public Accountant in New York. He holds a Master of Business Administration in Finance from the University of Rochester and a Bachelor of Business Administration in Accounting from Niagara University.



# Key Financial Metrics

## *Year ended March 31, 2024 -*

- **Gross profit margin improved 3%** in FY 2024 compared to FY 2023
- **Net loss improved 6%** in FY 2024 compared to FY 2023

## *Three months ended June 30, 2024 -*

- **European revenues increased 20%** compared to same period in 2023
- **Gross margin of 39%** compared to 35% in same period in 2023
- **Net loss improved 19%** compared to same period in 2023



# APPENDIX: Product Portfolio



# Diverse Product Portfolio

## United States

**Reliefacyn**  
Itch, Burn, Rash & Pain Care



**Regenacyn**  
Scar Gel



**Podiacyn**  
Everyday Foot Care



**Lumacyn**  
Clarifying Mist



**Microcyn Rx**  
Skin & Wound Care



**Acucyn**  
Eyelid & Eyelash Hygiene



**Nanocyn**  
Hospital Grade Disinfectant



**Ocucyn**  
Eyelid & Eyelash Cleanser



**Pediacyc**  
Skin Care & First Aid for Children



**Microcyn OTC**  
Wound & Skin Cleanser



**Rejuvacyn**  
Skin Repair



**Lasercyn**  
Dermal Spray



**Epicyn**  
Facial Cleanser



**Levicyn**  
Dermal Spray and Gel



**Celacyn**  
Scar Management Gel



# U.S. Dermatology



- Office dispense products exclusively for skin care professionals
- Generates highest margins for Sonoma
- Focused marketing to med spas and dermatology offices, which can resell products to their clients for a substantial margin



# U.S. Animal Health Care

**MicrocynAH<sup>®</sup>** family of advanced animal healthcare products, safe to use on pets and livestock, and perfect for hot spots, pink eye, scratches, skin rashes and ulcers, cuts, burns, post-surgical sites, irritated skin and lacerations.

- Sold in national pet-store retail chains and specialty stores such as **PetSmart**, **Tractor Supply**, **Cabela's**, **Bass Pro Shops** and **Menards**.



**MicrocynVS<sup>®</sup>** veterinarian-strength animal care for use in vet clinics and animal hospitals.



# EU Products

Solutions that work naturally **for everybody**

**Mucoclyns®**  
Decontamination solution



Exposure to  
germs and  
pathogens

**Microdacyn60®**  
Oral Care



Mouth and  
throat  
infections

**Sinudox®**  
Nasal care



Blocked nose or  
sinuses

**Ocudox®**  
Eye lid solution



Blepharitis  
treatment

**Epicyn®**  
Dermatology



Keloid or  
hypertrophic  
scar

**Gramaderm®**  
Dermatology



Acne  
treatment

**Pediacyn®**  
Dermatology



Atopic  
Dermatitis

**Microdacyn60®**  
Wound Care



**MicrocynAH®**  
Animal Health Care



# Direct-to-consumer products available through Shopify, Amazon and Amazon EU





# Middle East

## Microdacyn Wound Care



## Microsafe

Face Cool, Anti-Microbial, Baby Cool, Foot Cool, Lady Cool



## Microsafe

Disinfectant & Sanitizer



# Asia

## Singapore, Malaysia, Thailand, Indonesia



## China Microcyn



## Hong Kong Microdacyn60 Oral Care



## South Korea

BioDerm  
Wound Care

Biodacyn60



## The Philippines Microdacyn



## MicrocynAH®



## Latin America

### **Celacyn**

Scar Management Gel



### **Gramacyn**

Kit for Acne Skin



## Australia & New Zealand

### **Microdacyn**

Surgical Irrigation and  
Wound Treatment



### **Epicyn**

Treat Scars Right  
from the Start



### **Microdox**

Super-Oxidised Solution  
Bladder & Catheter Rinse





# THANK YOU

**Sonoma Pharmaceuticals Inc.**

5445 Conestoga Court, Suite 150 Boulder, CO 80301

United States of America

Phone: 1-(800) 759.9305

Email: [busdev@sonomapharma.com](mailto:busdev@sonomapharma.com)

Website: [www.sonomapharma.com](http://www.sonomapharma.com)



NASDAQ: SNOA